학술논문

Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial
Document Type
article
Source
Journal of the American Heart Association. 9(19)
Subject
Biomedical and Clinical Sciences
Cardiovascular Medicine and Haematology
Clinical Trials and Supportive Activities
Cardiovascular
Clinical Research
Good Health and Well Being
Cardiovascular Diseases
Double-Blind Method
Female
Health Status Indicators
Humans
Lower Extremity
Male
Middle Aged
Outcome Assessment
Health Care
Peripheral Arterial Disease
Platelet Aggregation Inhibitors
Quality of Life
Surveys and Questionnaires
Symptom Assessment
Ticagrelor
Vascular Surgical Procedures
Visual Analog Scale
health status instruments
peripheral artery disease
quality of life
Cardiorespiratory Medicine and Haematology
Cardiovascular medicine and haematology
Language
Abstract
Background There are limited data on health status instruments in patients with peripheral artery disease and cardiovascular and limb events. We evaluated the relationship between health status changes and cardiovascular and limb events. Methods and Results In an analysis of the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) trial, we examined the characteristics of 13 801 patients by tertile of health status instrument scores collected in the trial (EuroQol 5-Dimensions [EQ-5D], EQ visual analog scale [VAS], and peripheral artery questionnaire). We assessed the association between the baseline health status measurements and major adverse cardiovascular events, major adverse limb events, and lower-extremity revascularization procedures during trial follow-up and the association between 12-month health status change scores and subsequent end points during follow-up. There were 13 217 (95%) patients with EQ-5D scores, 13 533 (98%) with VAS scores, and 4431 (32%) with peripheral artery questionnaire scores. Patients in the lowest baseline EQ-5D tertile (0 to